Roche NimbleGen Q3 Sales Rise 22 Percent on Rising Sequence Capture, Array CGH Demand | GenomeWeb

By Justin Petrone

Increasing demand for target enrichment products and cytogenetic arrays helped Roche NimbleGen post a 22 percent rise in third-quarter revenue, the firm said last week.

In comparison, Roche's broader Applied Science business, a segment of the company's diagnostics division that encompasses Roche NimbleGen, decreased 2 percent during the third quarter, while the diagnostics division grew 1 percent and company-wide sales were down 7 percent for the quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.